Skip to main content

Table 4 In vitro and in vivo selection of de novo non-canonical INSTI resistance substitutions in HIV IN in tissue culture and in INSTI-naïve individuals

From: HIV drug resistance against strand transfer integrase inhibitors

Substitutions

RAL

EVG

DTG

CTG

BIC

Selection

In vitro

In vivo

In vitro

In vivo

In vitro

In vivo

In vitro

In vivo

In vitro

In vivo

R263K

R263K

  

X

 

X

X

  

X

 

M50I/R263K

    

X

   

X

 

A49G/S230R/R263K

     

X

    

M50I/S119R/R263K

    

X

     

H51Y/R263K

    

X

     

S119R/R263K

    

X

     

E138K/R263K

    

X

     

E138AKT/S147G/R263K

     

X

    

V151I/R263K

    

X

     

S153Y/R263K

    

X

     

V260I/R263K

     

X

    

Other

H51Y/G118R

    

X

     

V54I

X

         

G59E

X

         

L74M

 

X

 

X

 

X

    

Q95K

X

 

X

       

T97A

 

X

 

X

 

X

    

L101Y/T124A/S153Y

    

X

     

I203M

 

X

        

H114Y

  

X

       

G118R

 

X

  

X

     

F121Y

X

X

X

       

F121Y/G163R

X

         

F121Y/D232N

X

         

T124A

X

 

X

 

X

 

X

   

T124A/P145S

  

X

       

T124A/S153F

    

X

     

T124A/S153Y

      

X

   

T124A/Q146L

  

X

       

T125K

 

X

        

A128T

X

 

X

       

P145S

  

X

       

Q146L

      

X

   

Q146P

  

X

       

S147G

  

X

X

      

V151I

X

X

X

  

X

    

S153Y

      

X

   

M154I

 

X

        

E157Q

 

X

        

I162M

      

X

   

G163E

     

X

    

G163R

 

X

        

Q177R

  

X

       

G193E

    

X

     

S230R

X

X

X

       
  1. ‘X’ marks a report of the selection of a substitution or combination of substitutions. Numbers refer to amino acid position in HIV integrase, one letter amino acid code used
  2. References: [14, 18,19,20, 28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53]